List of Dojolvi drug patents

Dojolvi is owned by Ultragenyx Pharm Inc.

Dojolvi contains Triheptanoin.

Dojolvi has a total of 2 drug patents out of which 0 drug patents have expired.

Dojolvi was authorised for market use on 30 June, 2020.

Dojolvi is available in liquid;oral dosage forms.

Drug patent challenges can be filed against Dojolvi from June, 2024.

The generics of Dojolvi are possible to be released after 30 June, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(2 years from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Oct, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 30, 2027
New Chemical Entity Exclusivity (NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in